Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 301

2.

Oral Administration of Hoodia parviflora Alleviates Insulin Resistance and Nonalcoholic Steatohepatitis.

Mizrahi M, Ben Ya'acov A, Adar T, Levy Sklair M, Gaska S, Ilan Y.

J Med Food. 2019 Oct 21. doi: 10.1089/jmf.2019.0093. [Epub ahead of print]

PMID:
31634046
3.

Advanced Tailored Randomness: A Novel Approach for Improving the Efficacy of Biological Systems.

Ilan Y.

J Comput Biol. 2019 Aug 19. doi: 10.1089/cmb.2019.0231. [Epub ahead of print]

PMID:
31424268
4.

Why targeting the microbiome is not so successful: can randomness overcome the adaptation that occurs following gut manipulation?

Ilan Y.

Clin Exp Gastroenterol. 2019 May 8;12:209-217. doi: 10.2147/CEG.S203823. eCollection 2019. Review.

5.

β-Glycosphingolipids as Mediators of Both Inflammation and Immune Tolerance: A Manifestation of Randomness in Biological Systems.

Ilan Y.

Front Immunol. 2019 May 22;10:1143. doi: 10.3389/fimmu.2019.01143. eCollection 2019. Review.

6.

The heart-gut axis: new target for atherosclerosis and congestive heart failure therapy.

Forkosh E, Ilan Y.

Open Heart. 2019 Apr 23;6(1):e000993. doi: 10.1136/openhrt-2018-000993. eCollection 2019. Review.

7.

Randomness in microtubule dynamics: an error that requires correction or an inherent plasticity required for normal cellular function?

Ilan Y.

Cell Biol Int. 2019 Jul;43(7):739-748. doi: 10.1002/cbin.11157. Epub 2019 May 18. Review.

PMID:
31042006
8.

The role of microtubules in the immune system and as potential targets for gut-based immunotherapy.

Ilan-Ber T, Ilan Y.

Mol Immunol. 2019 Jul;111:73-82. doi: 10.1016/j.molimm.2019.04.014. Epub 2019 May 6. Review.

9.

Generating randomness: making the most out of disordering a false order into a real one.

Ilan Y.

J Transl Med. 2019 Feb 18;17(1):49. doi: 10.1186/s12967-019-1798-2. Review.

10.

Alpha-1 Anti-trypsin Exerts a Hepatoprotective Effect on Immune-mediated Hepatitis and Acetaminophen-induced Liver Injury.

Shabat Y, Ya'acov AB, Ilan Y.

J Clin Transl Hepatol. 2018 Dec 28;6(4):345-349. doi: 10.14218/JCTH.2018.00030. Epub 2018 Nov 5.

11.

Microtubules: From understanding their dynamics to using them as potential therapeutic targets.

Ilan Y.

J Cell Physiol. 2019 Jun;234(6):7923-7937. doi: 10.1002/jcp.27978. Epub 2018 Dec 10. Review.

PMID:
30536951
12.

Immune rebalancing by oral immunotherapy: A novel method for getting the immune system back on track.

Ilan Y.

J Leukoc Biol. 2019 Mar;105(3):463-472. doi: 10.1002/JLB.5RU0718-276RR. Epub 2018 Nov 26. Review.

PMID:
30476347
13.

Prevention of acetaminophen-induced liver injury by alginate.

Shteyer E, Ben Ya'acov A, Zolotaryova L, Sinai A, Slae M, Cohen S, Ilan Y.

Toxicol Appl Pharmacol. 2019 Jan 15;363:72-78. doi: 10.1016/j.taap.2018.11.008. Epub 2018 Nov 20.

PMID:
30468816
14.

Glycosphingolipids Prevent APAP and HMG-CoA Reductase Inhibitors-mediated Liver Damage: A Novel Method for "Safer Drug" Formulation that Prevents Drug-induced Liver Injury.

Mizrahi M, Adar T, Lalazar G, Nachman D, El Haj M, Ben Ya'acov A, Lichtenstein Y, Shabat Y, Kanovich D, Zolotarov L, Ilan Y.

J Clin Transl Hepatol. 2018 Jun 28;6(2):127-134. doi: 10.14218/JCTH.2017.00071. Epub 2018 Feb 14.

15.
16.

Primary sclerosing cholangitis is associated with abnormalities in CFTR.

Werlin S, Scotet V, Uguen K, Audrezet MP, Cohen M, Yaakov Y, Safadi R, Ilan Y, Konikoff F, Galun E, Mizrahi M, Slae M, Sayag S, Cohen-Cymberknoh M, Wilschanski M, Ferec C.

J Cyst Fibros. 2018 Sep;17(5):666-671. doi: 10.1016/j.jcf.2018.04.005. Epub 2018 May 26.

PMID:
29807875
17.

Analogy between non-alcoholic steatohepatitis (NASH) and hypertension: a stepwise patient-tailored approach for NASH treatment.

Ilan Y.

Ann Gastroenterol. 2018 May-Jun;31(3):296-304. doi: 10.20524/aog.2018.0248. Epub 2018 Mar 15. Review.

18.

Future of Treatment for Nonalcoholic Steatohepatitis: Can the Use of Safe, Evidence-Based, Clinically Proven Supplements Provide the Answer to the Unmet Need?

Ilan Y.

Dig Dis Sci. 2018 Jul;63(7):1726-1736. doi: 10.1007/s10620-018-5080-x. Epub 2018 Apr 20. Review.

PMID:
29679298
19.

Biomarkers for Nonalcoholic Steatohepatitis.

Ber TI, Ilan Y.

Gastroenterology. 2018 Apr;154(5):1546. doi: 10.1053/j.gastro.2017.12.042. Epub 2018 Mar 8. No abstract available.

PMID:
29526730
20.

Attenuating the rate of total body fat accumulation and alleviating liver damage by oral administration of vitamin D-enriched edible mushrooms in a diet-induced obesity murine model is mediated by an anti-inflammatory paradigm shift.

Drori A, Rotnemer-Golinkin D, Avni S, Drori A, Danay O, Levanon D, Tam J, Zolotarev L, Ilan Y.

BMC Gastroenterol. 2017 Nov 28;17(1):130. doi: 10.1186/s12876-017-0688-4.

21.

Oral Co-administration of Soy-derived Extracts with Alcohol or with Sugar-sweetened Beverages Exerts Liver and Sugar Protective Effects.

Khoury T, Rotnemer-Golinkin D, Shabat Y, Zolotarovya L, Ilan Y.

J Clin Transl Hepatol. 2017 Sep 28;5(3):208-215. doi: 10.14218/JCTH.2017.00019. Epub 2017 Jun 3.

22.

Oral Administration of CardioAid and Lunasin Alleviates Liver Damage in a High-Fat Diet Nonalcoholic Steatohepatitis Model.

Drori A, Rotnemer-Golinkin D, Zolotarov L, Ilan Y.

Digestion. 2017;96(2):110-118. doi: 10.1159/000479734. Epub 2017 Aug 11.

PMID:
28796993
23.

A synergistic effect of Cremophor and beta glucosylceramide to exert liver and sugar protection.

Shabat Y, Ilan Y.

J Food Sci Technol. 2017 Apr;54(5):1184-1191. doi: 10.1007/s13197-017-2520-0. Epub 2017 Mar 4.

24.

An oral administration of a recombinant anti-TNF fusion protein is biologically active in the gut promoting regulatory T cells: Results of a phase I clinical trial using a novel oral anti-TNF alpha-based therapy.

Almon E, Khoury T, Drori A, Gingis-Velitski S, Alon S, Chertkoff R, Mushkat M, Shaaltiel Y, Ilan Y.

J Immunol Methods. 2017 Jul;446:21-29. doi: 10.1016/j.jim.2017.03.023. Epub 2017 Apr 7.

PMID:
28392436
25.

Oral Administration of β-Glucosylceramide for the Treatment of Insulin Resistance and Nonalcoholic Steatohepatitis: Results of a Double-Blind, Placebo-Controlled Trial.

Lalazar G, Zigmond E, Weksler-Zangen S, Ya'acov AB, Levy MS, Hemed N, Raz I, Ilan Y.

J Med Food. 2017 May;20(5):458-464. doi: 10.1089/jmf.2016.3753. Epub 2017 Apr 7.

PMID:
28387617
26.

Impaired liver regeneration is associated with reduced cyclin B1 in natural killer T cell-deficient mice.

Ben Ya'acov A, Meir H, Zolotaryova L, Ilan Y, Shteyer E.

BMC Gastroenterol. 2017 Mar 23;17(1):44. doi: 10.1186/s12876-017-0600-2.

27.

Tocilizumab Promotes Regulatory T-cell Alleviation in STAT3 Gain-of-function-associated Multi-organ Autoimmune Syndrome.

Khoury T, Molho-Pessach V, Ramot Y, Ayman AR, Elpeleg O, Berkman N, Zlotogorski A, Ilan Y.

Clin Ther. 2017 Feb;39(2):444-449. doi: 10.1016/j.clinthera.2017.01.004. Epub 2017 Jan 30.

PMID:
28153428
28.

Combined beta-glucosylceramide and ambroxol hydrochloride in patients with Gaucher related Parkinson disease: From clinical observations to drug development.

Ishay Y, Zimran A, Szer J, Dinur T, Ilan Y, Arkadir D.

Blood Cells Mol Dis. 2018 Feb;68:117-120. doi: 10.1016/j.bcmd.2016.10.028. Epub 2016 Nov 12. Review.

PMID:
27866808
29.

Liver involvement in Gaucher disease - Review and clinical approach.

Adar T, Ilan Y, Elstein D, Zimran A.

Blood Cells Mol Dis. 2018 Feb;68:66-73. doi: 10.1016/j.bcmd.2016.10.001. Epub 2016 Oct 19. Review.

PMID:
27842801
30.

A plant cell-expressed recombinant anti-TNF fusion protein is biologically active in the gut and alleviates immune-mediated hepatitis and colitis.

Ilan Y, Gingis-Velitski S, Ben Ya'aco A, Shabbat Y, Zolotarov L, Almon E, Shaaltiel Y.

Immunobiology. 2017 Mar;222(3):544-551. doi: 10.1016/j.imbio.2016.11.001. Epub 2016 Nov 4.

PMID:
27832933
31.

Oral administration of a non-absorbable plant cell-expressed recombinant anti-TNF fusion protein induces immunomodulatory effects and alleviates nonalcoholic steatohepatitis.

Ilan Y, Ben Ya'acov A, Shabbat Y, Gingis-Velitski S, Almon E, Shaaltiel Y.

World J Gastroenterol. 2016 Oct 21;22(39):8760-8769.

32.
33.

Potential use of metabolic breath tests to assess liver disease and prognosis: has the time arrived for routine use in the clinic?

Stravitz RT, Ilan Y.

Liver Int. 2017 Mar;37(3):328-336. doi: 10.1111/liv.13268. Epub 2016 Nov 19. Review.

PMID:
27718326
34.

The gut-kidney axis in chronic renal failure: A new potential target for therapy.

Khoury T, Tzukert K, Abel R, Abu Rmeileh A, Levi R, Ilan Y.

Hemodial Int. 2017 Jul;21(3):323-334. doi: 10.1111/hdi.12486. Epub 2016 Sep 16. Review.

PMID:
27634464
35.

Compounds of the sphingomyelin-ceramide-glycosphingolipid pathways as secondary messenger molecules: new targets for novel therapies for fatty liver disease and insulin resistance.

Ilan Y.

Am J Physiol Gastrointest Liver Physiol. 2016 Jun 1;310(11):G1102-17. doi: 10.1152/ajpgi.00095.2016. Epub 2016 May 12. Review.

36.

Extracts from Lentinula edodes (Shiitake) Edible Mushrooms Enriched with Vitamin D Exert an Anti-Inflammatory Hepatoprotective Effect.

Drori A, Shabat Y, Ben Ya'acov A, Danay O, Levanon D, Zolotarov L, Ilan Y.

J Med Food. 2016 Apr;19(4):383-9. doi: 10.1089/jmf.2015.0111. Epub 2016 Mar 30.

PMID:
27027234
37.

Oral immune therapy: targeting the systemic immune system via the gut immune system for the treatment of inflammatory bowel disease.

Ilan Y.

Clin Transl Immunology. 2016 Jan 29;5(1):e60. doi: 10.1038/cti.2015.47. eCollection 2016 Jan. Review.

38.
39.

Suppression of Hepatocellular Carcinoma by Inhibition of Overexpressed Ornithine Aminotransferase.

Zigmond E, Ben Ya'acov A, Lee H, Lichtenstein Y, Shalev Z, Smith Y, Zolotarov L, Ziv E, Kalman R, Le HV, Lu H, Silverman RB, Ilan Y.

ACS Med Chem Lett. 2015 May 29;6(8):840-4. doi: 10.1021/acsmedchemlett.5b00153. eCollection 2015 Aug 13.

40.

Use of the methacetin breath test to classify the risk of cirrhotic complications and mortality in patients evaluated/listed for liver transplantation.

Stravitz RT, Reuben A, Mizrahi M, Lalazar G, Brown K, Gordon SC, Ilan Y, Sanyal A.

J Hepatol. 2015 Dec;63(6):1345-51. doi: 10.1016/j.jhep.2015.07.021. Epub 2015 Jul 26.

PMID:
26220750
41.

Immune therapy for hepatocellular carcinoma.

Ilan Y.

Hepatol Int. 2014 Sep;8 Suppl 2:499-504. doi: 10.1007/s12072-013-9501-9. Epub 2013 Dec 20.

PMID:
26201331
42.
43.

Oral mixture of autologous colon-extracted proteins for the Crohn's disease: A double-blind trial.

Israeli E, Zigmond E, Lalazar G, Klein A, Hemed N, Goldin E, Ilan Y.

World J Gastroenterol. 2015 May 14;21(18):5685-94. doi: 10.3748/wjg.v21.i18.5685.

44.

Oral Administration of OKT3 MAb to Patients with NASH, Promotes Regulatory T-cell Induction, and Alleviates Insulin Resistance: Results of a Phase IIa Blinded Placebo-Controlled Trial.

Lalazar G, Mizrahi M, Turgeman I, Adar T, Ben Ya'acov A, Shabat Y, Nimer A, Hemed N, Zolotarovya L, Lichtenstein Y, Lisovoder N, Samira S, Shalit I, Ellis R, Ilan Y.

J Clin Immunol. 2015 May;35(4):399-407. doi: 10.1007/s10875-015-0160-6. Epub 2015 Apr 17.

PMID:
25876706
45.

Oral administration of non-absorbable delayed release 6-mercaptopurine is locally active in the gut, exerts a systemic immune effect and alleviates Crohn's disease with low rate of side effects: results of double blind Phase II clinical trial.

Israeli E, Goldin E, Fishman S, Konikoff F, Lavy A, Chowers Y, Melzer E, Lahat A, Mahamid M, Shirin H, Nussinson E, Segol O, Ya'acov AB, Shabbat Y, Ilan Y.

Clin Exp Immunol. 2015 Aug;181(2):362-72. doi: 10.1111/cei.12640.

46.

Oral anti-CD3 immunotherapy for HCV-nonresponders is safe, promotes regulatory T cells and decreases viral load and liver enzyme levels: results of a phase-2a placebo-controlled trial.

Halota W, Ferenci P, Kozielewicz D, Dybowska D, Lisovoder N, Samira S, Shalit I, Ellis R, Ilan Y.

J Viral Hepat. 2015 Aug;22(8):651-7. doi: 10.1111/jvh.12369. Epub 2014 Nov 21.

PMID:
25412903
47.

β-glycosphingolipids ameliorated non-alcoholic steatohepatitis in the Psammomys obesus model.

Zigmond E, Tayer-Shifman O, Lalazar G, Ben Ya'acov A, Weksler-Zangen S, Shasha D, Sklair-Levy M, Zolotarov L, Shalev Z, Kalman R, Ziv E, Raz I, Ilan Y.

J Inflamm Res. 2014 Oct 8;7:151-8. doi: 10.2147/JIR.S50508. eCollection 2014.

48.

Reduced liver cell death using an alginate scaffold bandage: a novel approach for liver reconstruction after extended partial hepatectomy.

Shteyer E, Ben Ya'acov A, Zolotaryova L, Sinai A, Lichtenstein Y, Pappo O, Kryukov O, Elkayam T, Cohen S, Ilan Y.

Acta Biomater. 2014 Jul;10(7):3209-16. doi: 10.1016/j.actbio.2014.02.047. Epub 2014 Mar 5.

PMID:
24607858
49.

Impaired liver regeneration by β-glucosylceramide is associated with decreased fat accumulation.

Ben Ya'acov A, Lalazar G, Zolotaryova L, Steinhardt Y, Lichtentein Y, Ilan Y, Shteyer E.

J Dig Dis. 2013 Aug;14(8):425-32. doi: 10.1111/1751-2980.12062.

PMID:
23575221
50.

Immune therapy for nonalcoholic steatohepatitis: are we there yet?

Ilan Y.

J Clin Gastroenterol. 2013 Apr;47(4):298-307. doi: 10.1097/MCG.0b013e31827873dc. Review.

PMID:
23442833

Supplemental Content

Support Center